## **Supporting Information**

## MuSPAD sampling/survey period:

The blood sampling period took place from June 6th, 2022 to July 3rd, 2022. We chose three existing MuSPAD study sites: City Region Aachen (around 560,000 inhabitants), Magdeburg (around 236,000 inhabitants) and Hannover (around 536,000 inhabitants). From June 2022 on, we send out our online and paper-based survey to all established MuSPAD participants (Freiburg, Reutlingen, Chemnitz, Greifswald, Magdeburg, Hannover, Aachen, and Osnabrück).

## Lab analysis:

The serum samples obtained were analyzed centrally at the Institutes of Clinical Chemistry and Laboratory Medicine in Oldenburg and Greifswald. The Elecsys® Anti-SARS-CoV-2 S and Elecsys® Anti-SARS-CoV-2 NC (both Roche Diagnostics, Mannheim, Germany) were used for the determination of the quantitative antibody response against the S and N antigen of SARS-CoV-2. For Nucleocapsid (NC) protein we used  $\geq 0.8$  BAU/ml cut-offs for seropositivity. We also performed SARS-CoV-2 specific interferon-gamma release response (IGRA) using SARS-CoV-2 LIASION QuantiFERON-TB Gold Plus Qiagen®. For the blood collection, we used Lithium-Heparin Monovette and transferred them into specialized QFT-Plus Blood Collection with 24 h. We incubated the samples for 16 to 24 hours at 37°C, centrifuged the tubes at 2000 to 3000 RZB (g) for 15 minutes. Subsequently we detected released IFN $\gamma$  in harvested plasma by ELISA.

For the neutralization assay, we investigate the activity of heat-inactivated (56°C) serum against lentivirus (HIV)-based pseudoviruses. Our assay is a further development of the protocol of Crowford et al. <sup>25</sup>. In the methodology used, it was first described by us in the paper by Vanshylla et al.<sup>24</sup>. For our serum samples, the 50% inhibitory serum dilution (ID50) was tested against pseudoviruses with the spike protein of the Wu01 variant and the BA.4/5 variant. Samples were tested in a 1:3 dilution series at dilutions ranging from 1:10 to 1:21,870 - this is within the quantification range of the assay.

**Supplementary Table S1:** Protection against severe course of disease and infection in adults for different combinations of vaccination and infection with the Omicron variant<sup>1</sup>

Exposures	VE <sup>2</sup>	VE in studies without information on follow-	VE 0- 13 days	VE 14- 90 days	VE 91- 180 days	VE >180
		սթ				days
4	Infection <sup>3</sup>	46-96% (n=6)	36%	88-98%	72-96%	82%
Exposures			(n=1)	(n=2)	(n=2)	(n=1)
	Severe course of disease <sup>4</sup>	68-97% (n=4)				
	Death	81% (n=1)				
3	Infection <sup>3</sup>	35-78% (n=13)	18-69%	32-89%	5-96%	34-68%
Exposures			(n=8)	(n=14)	(n=10)	(n=3)
	Severe course of disease <sup>4</sup>	34-99%, AZ 30% (n=9)	65-95% (n=3)	59-97% (n=10)	52-95% (n=10)	65% (n=1)
	Death	66-98% (n=2)	71-86%	82-86%	87%	77% (n=1)
			(n=1)	(n=2)	(n=1)	~ /
1-2	Infection <sup>3</sup>	-6-90% (n=17)	10-23%	12-82%	3-70%	-13-
Exposures			(n=2)	(n=16)	(n=15)	56%
						(n=9)
	Severe course	41-97% (n=10)	28-46%	42-96%	22-91%	12-88%
	of disease4		(n=1)	(n=10)	(n=14)	(n=6)
	Death	66-90% (n=3)	-9-29%	60-62%	57-70%	49-57%
		. ,	(n=2)	(n=2)	(n=1)	(n=2)

<sup>1</sup> Interims analysis (see <u>https://zenodo.org/record/7177592#.Y4okYnbMI2w)</u> based on 27 identified studies from View hub on 9/27/2022; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, World Health Organization, Coalition for Epidemic Preparedness Innovations. Results of COVID-19 Vaccine Effectiveness Studies: An Ongoing Systematic Review: Weekly Summary Tables. Updated September 22, 2022. Available from: URL: <u>https://view-hub.org/sites/default/files/2022-</u>09/COVID19 Vaccine Effectiveness Transmission Studies Summary Tables 20220922.pdf.

<sup>2</sup> VE Vaccine effectiveness (reference: no vaccination, infection, or antibodies); range of point estimates of the included studies

<sup>3</sup> Definitions included every, symptomatic, or documented infection

<sup>4</sup> Definitions included hospitalization, admission on intensive care unit, and/or death

**Supplementary Table S2:** Combined endpoint in those with and without IGRA Age distribution of the MuSPAD participants with blood samples grouped by combined endpoints including IGRA test results

Age groups in years	18-34	35-49	50-64	65-79	80+	Overall
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%) <sup>1</sup>
Combined endpoints in	those with blo	ood sampling n	<b>n=2898</b>			
3 exposures + one in	85 (31.1%)	168	297	372	69 (51.5%)	991
2022		(35.1%)	(26.0%)	(42.7%)		(34.2%)
3 exposures	170	275	786	481	63 (47.0%)	1775
	(62.3%)	(57.5%)	(68.9%)	(55.2%)		(61.2%)
1-3 exposures, or no	18 (6.6%)	34 (7.1%)	51	15 (1.7%)	1 (0.7%)	119 (4.1%)
immune correlates			(4.5%)			
0 exposures, no	0 (0%)	1 (0.2%)	7 (0.6%)	4 (0.5%)	1 (0.7%)	13 (0.4%)
immune correlates						
Total	273	478	1141	872	134	2898
Combined endpoint i	ncluding IGRA	A result in thos	se with IGRA	A* sampling n=	=973 <sup>1,2</sup>	
3 exposures + one in	33; 27.0%	58; 31.2%;	60;	101; 36.9%	38; 23.6%	290, 29.8%
2022 (n; %IGRA	(5; 2%)	(5; 8.6%)	19.5%	(31;	(21;	(71;
negative)			(9;	30.7%)	55.3%)	24.5%)
			15.0%)			
3 exposures (n; %	81; 66.4%	103;	224;	168; 61.3%	45; 28.0%	621;
IGRA negative)	(21;	55.4%;	73.0%	(90;	(25;	63.8%
	25.9%)	(24;	(68;	53.6%)	55.6%)	(228;
		23.3%)	30.4%)			36.7%)
1-3 exposures, or no	8; 6.6%	24; 12.9%	21; 6.8%	3; 1.1%	0	56; 5.8%
immune correlates	(6; 75.0%)	(12;	(8;	(1; 33.3%)		(27;
(n; % IGRA		50.0%)	38.1%)			48.2%)
negative)						
0 exposures, no	0	1;0.5%	2; 0.7%	2; 0.7%	1; 0.6%	6; 0.6%
immune correlates		(1; 100%)	(2;	(2; 100%)	(100%)	(6; 100%)
(n; % IGRA			100%)			
negative)						
Total	122	186	307	274	84	973

\*IGRA= interferon-gamma release response; <sup>1</sup>43 participants did not specify age; <sup>2</sup>62 participants did not indicate a combined endpoint

**Supplementary Table S3:** Parametrization of the combined endpoints with and without humoral immune correlations as well as positive or negative IGRA based on literature synthesis

Groups of combine d endpoint s	Vaccination/Infection/Immun ity	Parametrizati on of models	Protection vs symptomati c infection for fully protected	Protection vs hospitalizatio n for fully protected	Protectio n vs ICU* for fully protected
Group I 3 + 1 exposure in 2022	3 exposures (vaccination or infection) with humoral immune correlates* + one infection/vaccination in 2022	Probably high protection vs severe course of disease Some protection vs infection	40-60%	70-90%	70-90%
Group II 3 exposure s	3 exposures (vaccination or infection) with humoral immune correlates*	Moderate protection vs severe course of disease Some protection vs infection	10-30%	50-70%	50-70%
Group III 1-3 exposure s or no immune correlate s	3 or more exposures without immune correlate, 1-2 exposures with or without immune correlate or 0 exposures with at least 1 positive humoral immune correlate*	Some protectio n vs severe course of disease Little protection vs infection	0	20-40%	20-40%

\*ICU= intensive care unit



**Supplementary Figure S1:** Scatterplot of correlation between anti-S by two variants Wu01 and BA.5 (A, B) and anti-NC antibody titers (C, D) based on ELISA test and neutralization



**Supplementary Figure S2:** Boxplot of BA.5 neutralizing antibody response by time since last SARS CoV-2 vaccination (a) and last SARS-CoV-2 infection (b) stratified by IGRA

**Supplementary Figure 3:** Weekly number of COVID 19 cases hospitalized, cumulated over all age groups in Germany

(https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\_Coronavirus/Daten/Klinische\_Aspekte. xlsx?\_\_blob=publicationFile

